Table 1.

Study characteristics.

Scheme	Country	Study Design	Duration (Weeks)	Sample Size		Mean Age †		Regimen		Diagnostic Criteria
				Intervention	Control	Intervention	Control	Intervention	Control
Sohaei et al. 2019 [42]	Iran	Double-blind RCT	6	27	24	29.4 (5.3)	29.6 (5.0)	Curcumin 500 mg BID	Placebo BID	Rotterdam criteria
Heshmati et al. 2020 [41]	Iran	Double-blind RCT	12	34	33	31.0 (5.2)	30.8 (8.0)	Curcumin 500 mg TID	Placebo (maltodextrin) TID	Rotterdam criteria
Jamilian et al. 2020 [40]	Iran	Double-blind RCT	12	26	24	28.6 (4.7)	27.2 (3.4)	Curcumin 500 mg QD	Placebo (starch) QD	Rotterdam criteria

^† Mean age is presented as mean (standard deviation). BID: twice per day; QD: once per day; RCT: randomized control trial; TID: three times per day.